Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Gastrointestinal Cancer Channel is supported with funding from Revolution Medicines (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO WCGIC 2020 | KEYNOTE-966: pembrolizumab, gemcitabine and cisplatin for CCA

Arndt Vogel, MD, Hannover Medical School, Hanover, Germany, discusses the rationale and study design of the KEYNOTE-966 trial (NCT04003636), evaluating pembrolizumab, gemcitabine and cisplatin in cholangiocarcinoma (CCA) patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Disclosures

Arndt Vogel, MD has had a speaker, consultancy and advisory role at Amgen, Roche, Bayer, Sanofi, BMS, Lilly, Novartis, EISAI, AstraZeneca, Merck, Incyte, Ipsen, PierreFabre, MSD, Sirtex, BTG, Servier, and Terumo.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.